cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1313Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMРефрактерная стенокардия: что мы можем предложить пациенту?Refractory angina: what to offer to our patients?ТерещенкоС. Н.TereshchenkoS. N.stereschenko@yandex.ruЖировИ. В.ZhirovI. V.stereschenko@yandex.ruМосковский государственный медицинский университет, МоскваРоссияMoscow State Medical University, MoscowRussian Federation20072008200764103106Copyright © Терещенко С.Н., Жиров И.В., 20072007Терещенко С.Н., Жиров И.В.Tereshchenko S.N., Zhirov I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1313

Рефрактерная стенокардия – сравнительно редкое состояние, которое, тем не менее, является актуальной проблемой современной кардиологии. В статье приведены определения этого заболевания, даны алгоритмы диагностики и терапии. Особое внимание уделено вопросам модулирования метаболизма в миокарде как патогенетического способа фармакотерапии рефрактерной стенокардии.

Refractory angina is a relatively rare state that nevertheless remains an important problem in modern cardiology. The article contains its definitions, diagnostics and management algorithms. The emphasis is put on myocardial metabolism modulation as pathogenetic method of refractory angina pharmacotherapy.

хроническая рефрактерная стенокардияэпидемиологиядиагностикалечениеchronic refractory anginaepidemiologydiagnosticstreatmentReferencesChester MR. Chronic refractory angina. Br J Cardiol 2000; 7: 108-11.Chester MR. Chronic refractory angina. Br J Cardiol 2000; 7: 108-11.Лупанов В.П. Диагностика и лечение рефрактерной стенокардии. РМЖ 2004; 12: 104-7.Лупанов В.П. Диагностика и лечение рефрактерной стенокардии. РМЖ 2004; 12: 104-7.Mannheimer C, Camici P, Chester M, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina.Eur Heart J 2002; 23: 355-70.Mannheimer C, Camici P, Chester M, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina.Eur Heart J 2002; 23: 355-70.Whitlow P, Dimas A, Bashore T, et al. Relationship of extent of revascularization with angina at one year in the Bypass Angioplasty Revascularization Investigation (BARI). JACC 1999; 34: 1750-9.Whitlow P, Dimas A, Bashore T, et al. Relationship of extent of revascularization with angina at one year in the Bypass Angioplasty Revascularization Investigation (BARI). JACC 1999; 34: 1750-9.CABRI Trial Participants. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet 1995; 346: 1179-84.CABRI Trial Participants. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet 1995; 346: 1179-84.Moore R, Groves D, Nolan J, et al. Altered short term heart rate variability with spinal cord stimulation in chronic refractory angina: evidence for the presence of procedure related cardiac sympathetic blockade. Heart 2004; 90: 211-2.Moore R, Groves D, Nolan J, et al. Altered short term heart rate variability with spinal cord stimulation in chronic refractory angina: evidence for the presence of procedure related cardiac sympathetic blockade. Heart 2004; 90: 211-2.Randle P, Garland P, Hales C, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-9.Randle P, Garland P, Hales C, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-9.Crozatier B, Badoual T, Boehm E, et al. Role of creatine kinase in cardiac excitation-contraction coupling: studies in creatine kinase-deficient mice. FASEB J 2002; 16: 653-60.Crozatier B, Badoual T, Boehm E, et al. Role of creatine kinase in cardiac excitation-contraction coupling: studies in creatine kinase-deficient mice. FASEB J 2002; 16: 653-60.Weiss RG, Chatham G, Georgakopoulos D, et al. An increase in the myocardial PCr/ATP ratio in GLUT4 null mice. FASEB J 2002; 16: 613-5.Weiss RG, Chatham G, Georgakopoulos D, et al. An increase in the myocardial PCr/ATP ratio in GLUT4 null mice. FASEB J 2002; 16: 613-5.Ingwall JS. Transgenesis and cardiac energetics: new insights into cardiac metabolism. J Mol Cell Cardiol 2004; 37: 613-23.Ingwall JS. Transgenesis and cardiac energetics: new insights into cardiac metabolism. J Mol Cell Cardiol 2004; 37: 613-23.Belke DD, Betuing S, Tuttle G, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002; 109: 629-39.Belke DD, Betuing S, Tuttle G, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002; 109: 629-39.Watanabe K, Fujii H, Katakashi T, et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 2000; 275: 2293-9.Watanabe K, Fujii H, Katakashi T, et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 2000; 275: 2293-9.Kantor P, Lucien A, Kozak P, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Cir Res 2000; 86: 580-8.Kantor P, Lucien A, Kozak P, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Cir Res 2000; 86: 580-8.Vladimir I. Influencing myocardial energy metabolism as a therapeutic principle. Clin Drug Invest 2004; 24: 731-8.Vladimir I. Influencing myocardial energy metabolism as a therapeutic principle. Clin Drug Invest 2004; 24: 731-8.Detry J, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279-88.Detry J, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279-88.Kolbel F, Bada V. Trimetazidine in geriatric patients with stable angina pectoris: the TIGER study. Int J Clin Pract 2003; 57: 867- 70.Kolbel F, Bada V. Trimetazidine in geriatric patients with stable angina pectoris: the TIGER study. Int J Clin Pract 2003; 57: 867- 70.Chaitman B, Scettino S, Parker J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. JACC 2004; 43: 1375-82.Chaitman B, Scettino S, Parker J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. JACC 2004; 43: 1375-82.Opie LH. The Heart. 3rd Ed. Philadelphia, Pa: Lippincott-Raven 1998.Opie LH. The Heart. 3rd Ed. Philadelphia, Pa: Lippincott-Raven 1998.Kates A, Herrero P, Dence C, et al. Impact of aging on substrate metabolism by the human heart. JAСC 2003; 41: 293-9.Kates A, Herrero P, Dence C, et al. Impact of aging on substrate metabolism by the human heart. JAСC 2003; 41: 293-9.Davila-Roman V, Vidala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. JACC 2002; 40: 271-7.Davila-Roman V, Vidala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. JACC 2002; 40: 271-7.Fisher DJ. Oxygenation and metabolism in the developing heart. Semin Perinatol 1984; 8: 217-25.Fisher DJ. Oxygenation and metabolism in the developing heart. Semin Perinatol 1984; 8: 217-25.Razeghi P, Young M, Alcorn J, et al. Metabolic gene expression in fetal and failing human heart. Circulation 2001; 104: 2923-31.Razeghi P, Young M, Alcorn J, et al. Metabolic gene expression in fetal and failing human heart. Circulation 2001; 104: 2923-31.

The authors declare that there are no conflicts of interest present.